Biotech industry shocked by Qiagen’s CEO resignation and halting of all genome sequencing device production

The biotech industry, research facilities, major hospitals and also the stock markets in US and Europe were in a state of shock about the news of the German genetic testing company disclosure of a reversal of its genome sequencing strategy and also the resignation of longtime CEO Peer Schatz.

Qiagen’s Ex CEO Peer Schatz.

Qiagen the maker of diagnostic kits for cancer and tuberculosis and al…